Berlin, June 28, 2022 – Bayer today announced the launch of Calantic™ Digital Solutions, a new platform delivering access to digital applications, including artificial intelligence (AI) enabled programs for medical imaging. The offering contains tools which aid radiologists and their teams to improve prioritization, lesion detection, quantification, and productivity. By providing access to AI radiology applications through the Calantic Digital Solutions platform Bayer will expand its comprehensive portfolio beyond contrast media, medical devices, software and services. The new platform will support healthcare professionals at all stages of their work, from diagnosis through treatment of their patients.
“AI has the potential to transform healthcare, and particularly in medical imaging it can turn the growing amounts of data into value-adding insights to support radiologists and their teams in their decision-making”, said Dr. Ryan Lee, Chair, Department of Radiology, Einstein Healthcare Network, Philadelphia, USA. “It is crucial to drive innovation in this area and broaden access to digital tools that can help address the rising demand for solutions which improve the speed and accuracy of diagnoses.”
“As a leader in key Radiology areas and building on our deep medical understanding across a multitude of diagnostic and therapeutic areas, Calantic Digital Solutions underlines our commitment to continue accelerating innovation for the benefit of patients and their physicians”, said Gerd Krueger, Head of Radiology, Bayer Pharmaceuticals. “With Calantic Digital Solutions, we are entering the fastest growing segment in the radiology market and taking the next step on our way from a product provider to a solution provider, following our mission to provide an ecosystem of third-party and Bayer products to deliver state-of-the art disease-oriented solutions for radiologists and their teams.”
Calantic Digital Solutions is a suite of digital radiology AI-enabled applications which assist radiologists and their teams at critical steps within a patient’s treatment journey. The vendor-neutral, cloud-hosted platform includes a growing number of applications designed to aid in prioritization, lesion detection and quantification, as well as apps that automate routine tasks and measurements, improve the radiology suites’ workflow, and free up time for radiologists and their teams. The offering is orchestrated by body region and procedure, initially focusing on thoracic and neurological diseases, such as pulmonary nodule detection and triage of potential intracerebral hemorrhage (ICH) and large vessel occlusions (LVO). ICH and LVO can be associated with stroke. More disease-specific application packages will be added moving forward. Bayer provides services around installation, configuration, and training of the platform and its applications. First launch markets will include the US and several European countries, with more regions to follow, upon local regulatory approvals as applicable.
About AI in Medical Imaging
With global sales of €400m, radiology AI is the fastest growing market segment within the overall global radiology market. It is expected to continue growing dynamically, with an estimated compounded annual growth rate of more than 25 percent through 2025. Innovation powered by AI is more needed than ever: aging populations and changing lifestyles are leading to an increase in chronic conditions such as cardiovascular disease and cancer. Consequently, the demand for medical imaging to detect diseases, guide treatment decisions and support therapy planning is growing. AI comes with the value proposition to accelerate diagnosis and increase the throughput of radiological examinations.
This is particularly important because time pressure and workload contribute to the prevalence of burn-out among radiologists. Aggravating this situation, there is a shortage of trained radiologists.1 In addition, publications show that the rate of diagnostic errors rises with long hours of overtime: a publication from 2018 speaks of approximately 40 million diagnostic errors involving imaging worldwide every year.2 Digital technologies can help manage the mounting workload of radiologists and their teams, ultimately striving to improve patient care.
About Radiology at Bayer
Everyone deserves clear answers about their health, starting with an early and accurate diagnosis. As a true life-science company with a heritage of over 100 years in Radiology, Bayer is committed to providing excellence, from innovative products to high-quality services. Bayer has a leading portfolio of contrast media for computed tomography (CT), X-Ray, and magnetic resonance imaging (MRI), devices for their precise administration, informatics solutions to support efficient and optimized patient care, as well as acknowledged educational programs that generated €1.8bn sales in 2021. Following the company’s ambition to outperform the radiology market’s average annual growth of 5% until 2030, Bayer is strongly committed to research and development, which includes leveraging artificial intelligence and driving innovation in medical imaging. Each of these offerings provide effective tools to support radiologists in their mission to deliver treatment critical answers and a clear direction – from diagnosis to care.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.